Influence of pre-surgical chemotherapy on liver parenchyma and post-surgical outcome of patients subjected to hepatectomy due to colorectal carcinoma metastases;Influencia de la quimioterapia preoperatoria en el parénquima hepático y en la evolución posquirúrgica de pacientes sometidos a hepatectomía por metástasis de carcinoma colorrectal

Cirugia Espanola

Volumn 88, Issue 6, 2010, Pages 404-412

  Gómez Ramírez, Joaquín ^a   Martín Pérez, Elena ^a   Gamallo Amat, Carlos ^a   García Sanz, Iñigo ^a   Bermejo, Elena ^a   Rodríguez, Ana ^a   Larrañaga, Eduardo ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

Chemotherapy; Liver metastases; Sinusoidal obstruction; Steatohepatitis

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE; IRINOTECAN; OXALIPLATIN; PLATINUM COMPLEX;

ARTICLE; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; COLORECTAL TUMOR; FATTY LIVER; FEMALE; HUMAN; LIVER RESECTION; LIVER TUMOR; LIVER VEIN OBSTRUCTION; MALE; METASTASIS; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PREOPERATIVE CARE; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; FATTY LIVER; FEMALE; HEPATECTOMY; HEPATIC VENO-OCCLUSIVE DISEASE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PREOPERATIVE CARE; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 78649713144     PISSN: 0009739X     EISSN: 1578147X     Source Type: Journal    
DOI: 10.1016/j.ciresp.2010.09.005     Document Type: Article

References (22)

1. Leichman L The role of chemotherapy in the curative treatment of patients with liver metastases from colorectal cancer. Surg Oncol Clin North Am 2007, 16:537-556.
2. Leonard GD, Brenner B, Kemeny NE Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma. J Clin Oncol 2005, 23:2038-2048.
3. Nordlinger B, Van Cutsem E, Gruenberger T, Glimelius B, Poston G, Rougier P, et al. Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. Ann Oncol 2009, 20:985-992.
4. Fernández FG, Ritter J, Goodwin JW, Linehan DC, Hawkins WG Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg 2005, 200:845-853.
5. Vauthey JN, Pawlik TM, Ribero D, Wu TT, Zorzi D, Hoff PM, et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006, 24:2065-2072.
6. Pawlik TM, Olino K, Gleisner AL, Torbenson M, Schulick R, Choti MA Preoperative chemotherapy for colorectal liver metastases: impact on hepatic histology and postoperative outcome. J Gastrointest Surg 2007, 11:860-868.
7. Rubbia-Brandt L, Audard V, Sartoretti P, Roth AD, Brezault C, Le Charpentier M, et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 2004, 15:460-466.
8. Mehta NN, Ravikumar R, Coldham CA, Buckels JA, Hubscher SG, Bramhall SR, et al. Effect of preoperative chemotherapy on liver resection for colorectal liver metastases. Eur J Surg Oncol 2008, 34:782-786.
9. Nakano H, Oussoultzoglou E, Rosso E, Casnedi S, Chenard-Neu MP, Dufour P, et al. Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann Surg 2008, 247:118-124.
10. Kandutsch S, Klinger M, Hacker S, Wrba F, Gruenberger B, Gruenberger T Patterns of hepatotoxicity after chemotherapy for colorectal cancer liver metastases. Eur J Surg Oncol 2008, 34:1231-1236.
11. Brouquet A, Benoist S, Julie C, Penna C, Beauchet A, Rougier P, et al. Risk factors for chemotherapy-associated liver injuries: A multivariate analysis of a group of 146 patients with colorectal metastases. Surgery 2009, 145:362-371.
12. Day C, James O Steatohepatitis: a tale of two «hits». Gastroenterology 1998, 114:842-845.
13. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005, 41:1313-1321.
14. Belgihiti J, Clavien PA The Brisbane 2000 terminology of liver anatomy and resections. HPB 2000, 2:333-339.
15. Karoui M, Penna C, Amin-Hashem M, Mitry E, Benoist S, Franc B, et al. Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg 2006, 243:1-7.
16. Aloia T, Sebagh M, Plasse M, Karam V, Lévi F, Giacchetti S, et al. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol 2006, 24:4983-4990.
17. Julie C, Lutz MP, Aust D, Kandutsch S, Collette L, Praet M, et al. Pathological analysis of hepatic injury after oxaliplatin-based neoadjuvant chemotherapy of colorectal cancer liver metastases: results of the EORTC Intergroup phase iii study 40983. ASCO. Gastrointestinal Cancers Symposium 2007.
18. Hubert C, Fervaille C, Sempoux C, Horsmans Y, Humblet Y, Machiels JP, et al. Prevalence and clinical relevance of pathological hepatic changes occurring after neoadjuvant chemotherapy for colorectal liver metastases. Surgery 2010, 147:185-194.
19. Ribero D, Wang H, Donadon M, Zorzi D, Thomas MB, Eng C, et al. Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer 2007, 110:2761-2767.
20. Klinger M, Eipeldauer S, Hacker S, Herberger B, Tamandl D, Dorfmeister M, et al. Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases. Eur J Surg Oncol 2009, 35:515-520.
21. Chun YS, Laurent A, Maru D, Vauthey JN Management of chemotherapy-associated hepatotoxicity in colorectal liver metastases. Lancet Oncol 2009, 10:278-286.
22. Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008, 371:1007-1016.